IQVIA Holdings Inc. (NYSE:IQV) Receives $267.87 Average PT from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average recommendation of “Moderate Buy” from the seventeen brokerages that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $267.87.

A number of research firms have recently weighed in on IQV. Barclays reduced their price target on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 15th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, October 14th. Evercore ISI dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Robert W. Baird raised their price objective on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Several large investors have recently modified their holdings of the stock. Cahaba Wealth Management Inc. acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $206,000. Raymond James & Associates grew its position in shares of IQVIA by 2.5% during the 3rd quarter. Raymond James & Associates now owns 820,771 shares of the medical research company’s stock worth $194,498,000 after buying an additional 20,397 shares during the period. Blue Trust Inc. grew its position in shares of IQVIA by 266.5% during the 3rd quarter. Blue Trust Inc. now owns 1,030 shares of the medical research company’s stock worth $244,000 after buying an additional 749 shares during the period. Net Worth Advisory Group acquired a new stake in IQVIA in the 3rd quarter valued at $259,000. Finally, Inspire Advisors LLC grew its position in IQVIA by 10.0% in the 3rd quarter. Inspire Advisors LLC now owns 2,348 shares of the medical research company’s stock valued at $557,000 after purchasing an additional 214 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.2 %

Shares of IQVIA stock opened at $236.69 on Friday. The firm’s 50-day moving average price is $239.08 and its two-hundred day moving average price is $231.08. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $43.15 billion, a price-to-earnings ratio of 30.74, a PEG ratio of 2.22 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period last year, the company posted $2.22 EPS. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, analysts forecast that IQVIA will post 10.25 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.